Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2021 09:20 ET | Source: Vaccitech (UK) Limited

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
November 12, 2021 21:55 ET | Source: Vaccitech (UK) Limited

Vaccitech의 VTP-300, 건강한 지원자 및 만성B형간염 환자 모두가 보유한 모든 표적 HBV 항원에 대해 우수한 내약성 및 T세포 유도 능력 보였다는 초기 결과 발표

HBV001 및 HBV002 연구의 초기 데이터, 만성B형간염(CHB) 환자의 경우 이종 프라임-부스트 벡터 조합인 ChAdOx1-HBV + MVA-HBV (VTP-300)가 B형간염 바이러스 항원 표적에 대해 강력한 T세포 면역 반응 유도 ChAdOx-1-HBV (HBV001) 단독으로 쓰일 경우 건강한 지원자 및 CHB 환자에 대한 내약성 뛰어나;...
November 12, 2021 21:55 ET | Source: Vaccitech (UK) Limited

在中期分析中，Vaccitech的VTP-300对健康志愿者和慢性HBV感染患者中都具有良好耐受性，并可诱发T细胞对抗所有靶向HBV抗原

HBV001和HBV002这两项研究的中期数据表明，在慢性乙型肝炎（CHB）患者中，ChAdOx1-HBV + MVA-HBV（VTP-300）的异源初免-加强载体组合诱发T细胞积极对抗靶向乙型肝炎病毒抗原。仅ChAdOx-1-HBV（HBV001）在健康志愿者和CHB患者中表现出良好的耐受性；VTP-300（HBV002）在CHB患者中表现出良好的耐受性。 ...
November 12, 2021 08:00 ET | Source: Vaccitech (UK) Limited

Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T...
November 12, 2021 07:00 ET | Source: Vaccitech (UK) Limited

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

OXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview...
November 10, 2021 08:00 ET | Source: Vaccitech (UK) Limited

Vaccitech to Present at the Jefferies London Healthcare Conference

OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
November 04, 2021 04:00 ET | Source: Vaccitech (UK) Limited

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford....
October 18, 2021 08:00 ET | Source: Vaccitech (UK) Limited

Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021

OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...
October 13, 2021 08:00 ET | Source: Vaccitech (UK) Limited

Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe

OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
September 09, 2021 08:00 ET | Source: Vaccitech (UK) Limited

Vaccitech to Present at Upcoming September Investor conferences

OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...